Ausgabe 3/2018
Inhalt (20 Artikel)
Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery
Mohammad Mahmoudian, Sara Salatin, Ahmad Yari Khosroushahi
Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer
Xiao-fang Guo, Sai-sai Li, Xiao-fei Zhu, Qiao-hua Dou, Duan Liu
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel
Chao Xu, Patanjali Ravva, Jun Steve Dang, Johann Laurent, Céline Adessi, Christine McIntyre, Georgina Meneses-Lorente, François Mercier
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Amita Patnaik, Michael Gordon, Frank Tsai, Kyri Papadopoulous, Drew Rasco, S. Muralidhar Beeram, Siqing Fu, Filip Janku, Scott M. Hynes, Sushma R. Gundala, Melinda D. Willard, Wei Zhang, Aimee Bence Lin, David Hong
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Amita Patnaik, Michael Gordon, Frank Tsai, Kyriakos P. Papadopoulos, Drew Rasco, Muralidhar Beeram, Siqing Fu, Filip Janku, Scott M. Hynes, Sushma R. Gundala, Melinda D. Willard, Wei Zhang, Aimee Bence Lin, David Hong
Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients
Sreenivasulu Palugulla, Panneer Devaraju, Smita Kayal, Sunil K. Narayan, Jayanthi Mathaiyan
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies
James J. Harding, Richard K. Do, Imane El Dika, Ellen Hollywood, Khrystyna Uhlitskykh, Emily Valentino, Peter Wan, Casey Hamilton, Xiaoxing Feng, Amanda Johnston, John Bomalaski, Chien-Feng Li, Eileen M. O’Reilly, Ghassan K. Abou-Alfa
Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin
L. van Andel, H. Rosing, M. M. Tibben, L. Lucas, R. Lubomirov, P. Avilés, A. Francesch, S. Fudio, A. Gebretensae, M. J. X. Hillebrand, J. H. M. Schellens, J. H. Beijnen
An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
Bodine P. S. I. Belderbos, Ronald de Wit, Caly Chien, Anna Mitselos, Peter Hellemans, James Jiao, Margaret K. Yu, Gerhardt Attard, Iurie Bulat, W. Jeffrey Edenfield, Fred Saad
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
Jong Hwan Choi, Woo Jin Chung, Si Hyun Bae, Do Seon Song, Myeong Jun Song, Young Seok Kim, Hyung Joon Yim, Young Kul Jung, Sang Jun Suh, Jun Yong Park, Do Young Kim, Seung Up Kim, Sung Bum Cho
Brazilin induces FOXO3A-dependent autophagic cell death by disturbing calcium homeostasis in osteosarcoma cells
Yan Kang, Peiheng He, Hua Wang, Yibiao Ye, Xing Li, Peigen Xie, Bowen Wu
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
Paul J. Wood, Robyn Strong, Grant A. McArthur, Michael Michael, Elizabeth Algar, Andrea Muscat, Lin Rigby, Melissa Ferguson, David M. Ashley
Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma
Guofu Chen, Liming Sheng, Xianghui Du
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors
Junji Furuse, Takayasu Kurata, Naohiro Okano, Yasuhito Fujisaka, Daisuke Naruge, Toshio Shimizu, Hiroshi Kitamura, Tsutomu Iwasa, Fumio Nagashima, Kazuhiko Nakagawa
Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer
Shravanti Bhowmik, Subhas Bhowmick, Kuntal Maiti, Amaresh Chakra, Pradeep Shahi, Deepak Jain, Thennati Rajamannar
A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
Laeeq Malik, Anthony Zwiebel, James Cooper
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
Millie Das, Sukhmani K. Padda, Adam Frymoyer, Julian Molina, Alex Adjei, Janet L. Lensing, Dale Miles, Branimir I. Sikic, Heather A. Wakelee
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation
Dehua Liao, Dunwu Yao, Ni Liu, Lizhi Cao, Daxiong Xiang, Nong Yang, Yongchang Zhang, Wenjuan Jiang, Chunhua Zhou
A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
Lixia Ju, Mingquan Han, Jinmei Su, Chunyan Wu, Zhengwei Dong
A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat
Cody J. Peer, Oliver M. Hall, Tristan M. Sissung, Richard Piekarz, Sanjeeve Balasubramaniam, Susan E. Bates, William D. Figg